Reply to Decroo et al.
Date:
06/15/2020
Topics:
Citation:
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH. Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1579-1580. doi: 10.1164/rccm.202002-0359LE. PMID: 32130866; PMCID: PMC7301745.
Abstract
No abstract available